BR9608592A - Esteróides neuroativos da série do androstano e do pregnano - Google Patents

Esteróides neuroativos da série do androstano e do pregnano

Info

Publication number: BR9608592A
Authority: BR; Brazil
Prior art keywords: derivatives; androstane; grc; alpha; hydroxy
Prior art date: 1995-06-06

Application number

BR9608592A

Other languages

English (en)

Inventor

Ravindra B Upasani

David B Fick

Derk J Hogenkamp

Nancy C Lan

Original Assignee

Cocensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1996-06-06

Publication date

1999-06-29

1996-06-06 Application filed by Cocensys Inc filed Critical Cocensys Inc

1999-06-29 Publication of BR9608592A publication Critical patent/BR9608592A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR9608592A 1995-06-06 1996-06-06 Esteróides neuroativos da série do androstano e do pregnano BR9608592A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46740495A	1995-06-06	1995-06-06
PCT/US1996/010115 WO1996040043A2 (en)	1995-06-06	1996-06-06	Neuroactive steroids of the androstane and pregnane series

Publications (1)

Publication Number	Publication Date
BR9608592A true BR9608592A (pt)	1999-06-29

Family

ID=23855552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9608592A BR9608592A (pt)	1995-06-06	1996-06-06	Esteróides neuroativos da série do androstano e do pregnano

Country Status (23)

Country	Link
US (1)	US5925630A (pt)
EP (2)	EP1288220A3 (pt)
JP (1)	JP4145350B2 (pt)
KR (1)	KR19990022323A (pt)
CN (1)	CN1190404A (pt)
AT (1)	ATE284895T1 (pt)
AU (1)	AU725214B2 (pt)
BR (1)	BR9608592A (pt)
CA (1)	CA2223996A1 (pt)
CZ (1)	CZ394197A3 (pt)
DE (1)	DE69634039T2 (pt)
ES (1)	ES2235187T3 (pt)
FI (1)	FI974448L (pt)
GE (1)	GEP20012530B (pt)
HU (1)	HUP9901138A3 (pt)
IL (1)	IL122348A0 (pt)
NO (1)	NO311805B1 (pt)
NZ (1)	NZ310850A (pt)
PL (1)	PL185523B1 (pt)
PT (1)	PT837874E (pt)
RU (1)	RU2194712C2 (pt)
UA (1)	UA57706C2 (pt)
WO (1)	WO1996040043A2 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070129282A1 (en) *	1998-11-24	2007-06-07	Ahlem Clarence N	Pharmaceutical treatments and compositions
WO2000050034A1 (en) *	1999-02-24	2000-08-31	The Regents Of The University Of California	Gaba receptors mediate inhibition of t cell responses
EP1449846A1 (en) *	1999-04-29	2004-08-25	Euro-Celtique S.A.	3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
YU77701A (sh) *	1999-04-29	2005-07-19	Euro-Celtique S.A.	3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
EP1228083A2 (en) *	1999-09-30	2002-08-07	Hollis-Eden Pharmaceuticals Inc.	Therapeutic treatment of androgen receptor driven conditions
GB2363983A (en)	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
US20020072509A1 (en) *	2000-10-11	2002-06-13	Stein Donald Gerald	Methods for the treatment of a traumatic central nervous system injury
AR031473A1 (es) *	2000-11-20	2003-09-24	Lundbeck & Co As H	Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
GR1003861B (el) *	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
RU2182004C1 (ru) *	2001-02-22	2002-05-10	Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан"	Лекарственный препарат для парентерального применения
AU2002244247B2 (en)	2001-03-01	2007-12-13	Harbor Biosciences, Inc.	Use of certain steroids for treatment of blood cell deficiencies
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
WO2004089304A2 (en) *	2003-04-01	2004-10-21	Hollis-Eden Pharmaceuticals, Inc.	Antiandrogens with marginal agonist activity and methods of use
EP1715921B1 (en) *	2003-09-25	2013-04-24	Abraxis BioScience, Inc.	Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) *	2003-11-10	2005-05-19	Helton David R.	Composition and method for treating emesis
WO2006012563A2 (en) *	2004-07-23	2006-02-02	The Regents Of The University Of California	Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
RU2289403C2 (ru) *	2004-07-30	2006-12-20	Государственное учреждение Научно-исследовательский институт фармакологии им. В.В. Закусова Российской Академии медицинских наук	Фармацевтическая композиция на основе афобазола
CA2582231A1 (en) *	2004-09-29	2006-10-19	Hollis-Eden Pharmaceuticals, Inc.	Steroid analogs and uses
US20060211667A1 (en) *	2005-03-21	2006-09-21	Eric Marchewitz	Use of pregnane steroid derivatives for enhancing physical performance
PL1868614T3 (pl) *	2005-03-24	2013-01-31	Univ Emory	Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
US7473687B2 (en) *	2005-03-24	2009-01-06	Emory University	Methods for the treatment of a traumatic central nervous system injury
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) *	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2377531A2 (en)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogenesis by modulating angiotensin
MX2008014320A (es)	2006-05-09	2009-03-25	Braincells Inc	Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7998971B2 (en)	2006-09-08	2011-08-16	Braincells Inc.	Combinations containing a 4-acylaminopyridine derivative
HUE036410T2 (hu)	2006-11-21	2018-07-30	Asarina Pharma Ab	Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
RU2326671C1 (ru) *	2007-03-30	2008-06-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА)	Средство для модуляции дофаминовых рецепторов головного мозга при менопаузе
US20100204192A1 (en)	2007-06-11	2010-08-12	University Of Sourthern California	Agents, compositions and methods for enhancing neurological function
JP2010530371A (ja) *	2007-06-11	2010-09-09	ユニバーシティオブサザンカリフォルニア	神経学的機能を増強するための作用物質、組成物および方法
WO2009062134A1 (en) *	2007-11-09	2009-05-14	Cenomed Biosciences, Llc	Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) *	2008-04-18	2009-10-22	David Helton	Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101585862B (zh) *	2008-05-20	2014-12-17	梅克芳股份公司	甾族化合物
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2012050907A2 (en)	2010-09-28	2012-04-19	The Regents Of The University Of California	Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012116290A2 (en)	2011-02-25	2012-08-30	Washington University	Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CA2843436A1 (en) *	2011-07-29	2013-02-07	The Regents Of The University Of California	Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
AU2012304412A1 (en) *	2011-09-08	2014-03-27	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
PT2766380T (pt) *	2011-10-14	2019-07-29	Sage Therapeutics Inc	Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
RS59734B1 (sr)	2012-01-23	2020-02-28	Sage Therapeutics Inc	Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
US20130281418A1 (en) *	2012-04-23	2013-10-24	Eric D. Marchewitz	Use of hydroxypregnenolone derivatives for enhancing health and physical performance
EP2887944B1 (en)	2012-08-21	2021-10-06	Sage Therapeutics, Inc.	Allopregnanolone for treating refractory status epilepticus
CN102816198A (zh) *	2012-09-08	2012-12-12	广西师范学院	具有氨衍生物支链结构的3-羟基-5-烯甾体化合物制备方法及其在抗肿瘤药物中的应用
CN102924554B (zh) *	2012-10-29	2015-07-22	中国科学院昆明植物研究所	C-3,11,12,20-四取代c-21甾体类衍生物及其药物组合物和其在医药中的应用
EP2925327B1 (en)	2012-11-30	2024-01-10	The Regents of The University of California	Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
KR102400891B1 (ko) *	2012-12-18	2022-05-20	워싱톤 유니버시티	신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
EP2956466A4 (en) *	2013-02-15	2016-11-02	Univ Washington	NEUROACTIVE ENANTIOMERS 15, 16 AND 17 SUBSTITUTED STEROIDS AS MODULATORS FOR GABA-A RECEPTORS
US9512170B2 (en)	2013-03-01	2016-12-06	Washington University	Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en)	2013-03-11	2016-06-14	Washington University	Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
PT2968369T (pt)	2013-03-13	2018-12-05	Sage Therapeutics Inc	Esteroides neuroativos e métodos para o seu uso
US9562026B2 (en)	2013-03-14	2017-02-07	Washington University	Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169831A1 (en)	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
PL2986624T3 (pl)	2013-04-17	2020-11-16	Sage Therapeutics, Inc.	Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia
WO2014169836A1 (en) *	2013-04-17	2014-10-23	Sage Therapeutics, Inc.	19-nor neuroactive steroids and methods of use thereof
KR102614507B1 (ko)	2013-04-17	2023-12-19	세이지 테라퓨틱스, 인크.	19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
CA3199003A1 (en)	2013-07-19	2015-01-22	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
HUE052308T2 (hu)	2013-08-23	2021-04-28	Sage Therapeutics Inc	Neuroaktív szteroidok, készítmények és alkalmazásuk
US10246482B2 (en)	2014-06-18	2019-04-02	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
WO2016036724A1 (en)	2014-09-02	2016-03-10	The Texas A&M University System	Method of treating organophosphate intoxication
JOP20200195A1 (ar)	2014-09-08	2017-06-16	Sage Therapeutics Inc	سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3206493B1 (en)	2014-10-16	2020-05-06	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
CN117024502A (zh)	2014-10-16	2023-11-10	萨奇治疗股份有限公司	靶向cns障碍的组合物和方法
EP3719029A1 (en)	2014-11-27	2020-10-07	Sage Therapeutics, Inc.	Compositions for inducing sedation
TWI748936B (zh)	2015-01-12	2021-12-11	瑞典商優鎂奎認知Ａｂ公司	新穎化合物
ES2857082T3 (es)	2015-01-26	2021-09-28	Sage Therapeutics Inc	Composiciones y métodos para el tratamiento de trastornos del SNC
JP6875996B2 (ja)	2015-02-20	2021-05-26	セージセラピューティクス，インコーポレイテッド	神経刺激性ステロイド、組成物、およびその使用
EP3319610A4 (en)	2015-07-06	2019-03-06	Sage Therapeutics, Inc.	OXYSTEROLS AND METHOD OF USE THEREOF
PT3319612T (pt) *	2015-07-06	2021-08-24	Sage Therapeutics Inc	Oxisteróis e métodos de utilização dos mesmos
CN113292623A (zh)	2015-07-06	2021-08-24	萨奇治疗股份有限公司	孕甾醇及其使用方法
AU2017229656B2 (en)	2016-03-08	2022-09-29	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
ES2921010T3 (es)	2016-04-01	2022-08-16	Sage Therapeutics Inc	Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
AU2017296295B2 (en)	2016-07-11	2022-02-24	Sage Therapeutics, Inc.	C7, C12, and C16 substituted neuroactive steroids and their methods of use
MA45599A (fr) *	2016-07-11	2019-05-15	Sage Therapeutics Inc	Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
CN106265685A (zh) *	2016-09-18	2017-01-04	南通大学	没药甾酮z在制备抗抑郁症药物中的应用
ES2935057T3 (es)	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
EP4105223B1 (en)	2016-10-18	2025-04-30	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
BR112019008032A2 (pt)	2016-10-18	2019-09-03	Sage Therapeutics, Inc.	oxiesteróis e métodos de uso dos mesmos
WO2019075362A1 (en) *	2017-10-12	2019-04-18	Sage Therapeutics, Inc.	METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
JP7538040B2 (ja)	2018-01-12	2024-08-21	セージセラピューティクス，インコーポレイテッド	ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
CN114805462B (zh) *	2018-02-11	2024-06-18	江苏豪森药业集团有限公司	一种甾族类衍生物调节剂及其制备方法和应用
AU2019217320B2 (en) *	2018-02-11	2023-12-21	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Steroid derivative regulators, method for preparing the same, and uses thereof
US10562930B1 (en)	2018-08-31	2020-02-18	Praxis Precision Medicines, Inc.	Salts and crystal forms of GABAA positive allosteric modulator
CN116425819B (zh) *	2019-01-08	2025-10-03	成都康弘药业集团股份有限公司	甾体类化合物、用途及其制备方法
WO2020243488A1 (en) *	2019-05-31	2020-12-03	Sage Therapeutics, Inc.	Neuroactive steroids and compositions thereof
WO2021188778A2 (en) *	2020-03-18	2021-09-23	Sage Therapeutics, Inc.	Neuroactive steroids and their methods of use
EP4153182A4 (en) *	2020-05-18	2024-05-29	Vistagen Therapeutics, Inc.	TREATMENT OF ADAPTATION DISORDERS
RU2739247C1 (ru) *	2020-09-14	2020-12-22	Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан"	Способ получения лекарственного препарата для парентерального применения
WO2023060067A1 (en)	2021-10-04	2023-04-13	Marinus Pharmaceuticals, Inc.	Amorphous solid dispersion ganaxolone formulation
EP4429669A1 (en)	2021-11-10	2024-09-18	Umecrine AB	Steroid as a modulator of gabaa receptor
US20240383941A1 (en)	2021-11-10	2024-11-21	Umecrine Ab	3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor
WO2023083979A1 (en)	2021-11-10	2023-05-19	Umecrine Ab	3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US20240408124A1 (en)	2023-05-31	2024-12-12	Rubedo Life Sciences, Inc.	GPX4 Inhibitors and Senolytic Compounds and Uses Thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1050765B (de) *		1959-02-19	Les Laboratoires Fran?ais de Chimiotherapie, Paris	Verfahren zur Herstellung von Testan-3a-ol-ll-on und seinen Estern
GB839911A (en) *	1957-01-29	1960-06-29	Chimiotherapie Lab Franc	Derivatives of etiocholane and the preparation thereof
US3135744A (en) *	1961-04-12	1964-06-02	Vismara Francesco Spa	Cycloalkenyl ethers of 17 beta-hydroxy androstanes
FR1437361A (fr) *	1962-06-28	1966-05-06	Vismara Francesco Spa	Procédé de préparation de nouveaux éthers alcényliques de 17beta-hydroxy-androstanes
US3316146A (en) *	1964-03-30	1967-04-25	Upjohn Co	Method of inducing sedation and muscle relaxation
GB1376892A (en) *	1970-11-12	1974-12-11	Glaxo Lab Ltd	2beta-substituted-3alpha-hydroxysteroids and their esters
US3969345A (en) *	1970-12-17	1976-07-13	Glaxo Laboratories Limited	20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
US3953429A (en) *	1970-12-17	1976-04-27	Glaxo Laboratories Limited	Anaesthetic steroids of the androstance and pregnane series
GB1377608A (en) *	1970-12-17	1974-12-18	Glaxo Lab Ltd	3alpha-hydroxy or acyloxy pregnene-21-ethers
GB1380248A (en) *	1970-12-17	1975-01-08	Glaxo Lab Ltd	3alpha-hydroxy steroids and esters thereof
US3943124A (en) *	1970-12-17	1976-03-09	Gordon Hanley Phillipps	Chemical compounds
GB1409239A (en) *	1971-11-11	1975-10-08	Glaxo Lab Ltd	Process for the preparation of 3alpha-hydroxy-5alpha-steroids
US3959260A (en) *	1972-05-05	1976-05-25	Glaxo Laboratories Limited	Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
GB1432135A (en) *	1972-05-05	1976-04-14	Glaxo Lab Ltd	21-substituted pregnanes
GB1436324A (en) *	1972-05-12	1976-05-19	Glaxo Lab Ltd	Anaesthetic 3alpha-hydroxy pregnanes
US4192871A (en) *	1976-01-06	1980-03-11	Glaxo Laboratories Limited	Chemical compounds
US4197296A (en) *	1977-03-23	1980-04-08	Glaxo Group Limited	Androstanes
GB1581235A (en) *	1977-04-04	1980-12-10	Glaxo Operations Ltd	11a-amino-3a-hydroxy-steroids
US4297350A (en) *	1978-10-10	1981-10-27	The Upjohn Company	Male contraceptive steroids and methods of use
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
US5319115A (en) *	1987-08-25	1994-06-07	Cocensys Inc.	Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5208227A (en) *	1987-08-25	1993-05-04	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
US5232917A (en) *	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0701444B1 (en) *	1993-05-24	2010-04-07	Purdue Pharma Ltd.	Methods and compositions for inducing sleep
BR9506779A (pt) *	1994-02-14	1997-10-14	Cocensys Inc	Composto composição farmacéutica método para modular o complexo ionóforo receptor gaba-cloreto em um paciente animal pela ligação ao sitio neuroesteróide no dito complexo método para tratar ou evitar estresse ou ansiedade em um paciente animal método para aliviar ou evitar isônia pms ou pnd em um paciente animal método para tratar ou evitar perturbacões na disposicão de ánimo em um paciente animal e método para induzir anestesia em um paciente animal
BR9509764A (pt) *	1994-11-23	1998-07-07	Cocensys Inc	Série androstano e pregnano para modulação alostérica de receptor de gaba

1996
- 1996-06-06 PL PL96323718A patent/PL185523B1/pl unknown
- 1996-06-06 CN CN96195360A patent/CN1190404A/zh active Pending
- 1996-06-06 ES ES96919372T patent/ES2235187T3/es not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/010115 patent/WO1996040043A2/en not_active Ceased
- 1996-06-06 AU AU61725/96A patent/AU725214B2/en not_active Ceased
- 1996-06-06 AT AT96919372T patent/ATE284895T1/de active
- 1996-06-06 DE DE69634039T patent/DE69634039T2/de not_active Expired - Lifetime
- 1996-06-06 US US08/659,192 patent/US5925630A/en not_active Expired - Lifetime
- 1996-06-06 CA CA002223996A patent/CA2223996A1/en not_active Abandoned
- 1996-06-06 UA UA98010025A patent/UA57706C2/uk unknown
- 1996-06-06 IL IL12234896A patent/IL122348A0/xx not_active IP Right Cessation
- 1996-06-06 HU HU9901138A patent/HUP9901138A3/hu unknown
- 1996-06-06 FI FI974448A patent/FI974448L/fi unknown
- 1996-06-06 CZ CZ973941A patent/CZ394197A3/cs unknown
- 1996-06-06 EP EP02025321A patent/EP1288220A3/en not_active Ceased
- 1996-06-06 RU RU98100755/04A patent/RU2194712C2/ru not_active IP Right Cessation
- 1996-06-06 KR KR1019970708803A patent/KR19990022323A/ko not_active Ceased
- 1996-06-06 EP EP96919372A patent/EP0837874B1/en not_active Expired - Lifetime
- 1996-06-06 PT PT96919372T patent/PT837874E/pt unknown
- 1996-06-06 BR BR9608592A patent/BR9608592A/pt not_active IP Right Cessation
- 1996-06-06 NZ NZ310850A patent/NZ310850A/xx not_active IP Right Cessation
- 1996-06-06 GE GEAP19964051A patent/GEP20012530B/en unknown
- 1996-06-06 JP JP50221097A patent/JP4145350B2/ja not_active Expired - Fee Related
1997
- 1997-12-04 NO NO19975608A patent/NO311805B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0837874A2 (en)	1998-04-29
NZ310850A (en)	1999-07-29
EP1288220A3 (en)	2004-07-21
CZ394197A3 (cs)	1998-06-17
NO975608D0 (no)	1997-12-04
NO975608L (no)	1998-02-06
US5925630A (en)	1999-07-20
HUP9901138A2 (hu)	1999-07-28
WO1996040043A3 (en)	1997-03-27
MX9709384A (es)	1998-10-31
AU725214B2 (en)	2000-10-05
NO311805B1 (no)	2002-01-28
EP1288220A2 (en)	2003-03-05
DE69634039T2 (de)	2005-12-08
KR19990022323A (ko)	1999-03-25
FI974448A0 (fi)	1997-12-05
GEP20012530B (en)	2001-09-25
PL323718A1 (en)	1998-04-14
JP4145350B2 (ja)	2008-09-03
DE69634039D1 (de)	2005-01-20
AU6172596A (en)	1996-12-30
WO1996040043A2 (en)	1996-12-19
IL122348A0 (en)	1998-04-05
ES2235187T3 (es)	2005-07-01
JPH11507643A (ja)	1999-07-06
UA57706C2 (uk)	2003-07-15
FI974448A7 (fi)	1997-12-05
PT837874E (pt)	2005-03-31
PL185523B1 (pl)	2003-05-30
HUP9901138A3 (en)	1999-11-29
RU2194712C2 (ru)	2002-12-20
FI974448L (fi)	1997-12-05
CN1190404A (zh)	1998-08-12
ATE284895T1 (de)	2005-01-15
CA2223996A1 (en)	1996-12-19
EP0837874B1 (en)	2004-12-15

Publication	Publication Date	Title
BR9608592A (pt)	1999-06-29	Esteróides neuroativos da série do androstano e do pregnano
DE122012000012I1 (de)	2012-06-14	17-Substituierte steroide, verwendbar bei behandlung von krebs.
DK0582338T3 (da)	2000-03-20	17-spiromethylensteroider
CA2093808A1 (en)	1993-02-14	Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DE59510092D1 (de)	2002-04-11	Hapten-markierte peptide
ATE128983T1 (de)	1995-10-15	17-spirofuran-3'-yliden steroide.
PT78743A (de)	1984-07-01	1-alkyl-androsta-1,4-dien-3,17-dione verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
ATE152119T1 (de)	1997-05-15	Neue 16-methyl substituierte steroidderivate von pregna-1,4-dien-3,20-dion, ihre herstellung, ihre verwendung zur herstellung von 16-methylene- substituierte steroide und neue zwischenprodukten dafür
GB1458372A (en)	1976-12-15	Steroid carbamates and allophanates
CA2096020A1 (en)	1992-05-31	2.beta.,19-methyleneamino bridged steroids as aromatase inhibitors
ATE277071T1 (de)	2004-10-15	Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
GB1427645A (en)	1976-03-10	Pregnane derivative its preparation and compositions thereof
JPS51149258A (en)	1976-12-22	A process for preparing steroid derivatives
NO944999D0 (no)	1994-12-23	Fremgangsmåte for steroide peracylglykosider
GB1267398A (en)	1972-03-15	PROCESS FOR THE MANUFACTURE OF 11beta-HYDROXY-5alpha,6alpha-EPOXY-STEROIDS
NZ333837A (en)	2000-05-26	estrene steroids for inducing hypothalamic effects
ATE138932T1 (de)	1996-06-15	17-(pyridazin-n-oxyd)-substituierte steroide mit cardiotonischer wirksamkeit

Legal Events

Date	Code	Title	Description
2007-01-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A E 10A ANUIDADES.
2011-12-06	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1882 DE 30/01/2007.